By addressing each community’s unique needs with tailored, culturally responsive care and cross-sector collaboration, we can empower healthcare providers to drive lasting, equitable outcomes.
This week at HLTH, Dexcom COO Jake Leach discussed Stelo, his company's new product. Stelo is an over-the-counter continuous glucose monitor meant for all adults who don't take insulin.
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health.
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
The FDA rejected Novo Nordisk’s biologics license application for icodec, citing questions about the manufacturing process for this once weekly insulin as well as its use by type 1 diabetes patients. But there are several high-profile FDA approvals in our recap of recent regulatory news.
Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market. It will soon be available in U.S. retail pharmacies and medical equipment suppliers.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
No one should ever learn about CKD after their kidneys have already failed.
Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.
By working together to build an ecosystem of support around people with diabetes, the healthcare system as a whole can ensure that no one slips through the cracks.
Johns Hopkins Hospital teamed up with Healthy.io, a company that offers smartphone-based technology to improve wound care management for diabetic patients. The partners are conducting a 120-person study to measure the impact of the startup’s technology.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Biolinq raked in $58 million in capital this week. The company is developing a wearable patch that uses electrochemical sensors to measure a person’s glucose levels from the intradermal space just beneath the surface of their skin.
A new report from the Peterson Health Technology Institute analyzed eight digital diabetes management tools. It found that the tools don't provide meaningful clinical benefits and increase healthcare spending.
Valendo Health, the newest startup built at Redesign Health, launched on Tuesday. The company partners with independent endocrinology practices and provides technology to help them thrive in value-based care arrangements.
Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.
New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.